NCT04941664 Minimum Effective Local Anesthetic Volume for Ultrasound Guided Superior Trunk Block
| NCT ID | NCT04941664 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Chinese University of Hong Kong |
| Condition | Musculoskeletal Diseases or Conditions |
| Study Type | INTERVENTIONAL |
| Enrollment | 25 participants |
| Start Date | 2023-01-19 |
| Primary Completion | 2026-07-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 25 participants in total. It began in 2023-01-19 with a primary completion date of 2026-07-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The objective of this study is to identify the minimum effective dosage of a commonly used local anaesthetic drug "levobupivacaine" required to produce an effective ultrasound guided (USG) superior trunk block (STB) in at least 90% of patients for shoulder arthroscopic surgeries.
Eligibility Criteria
Inclusion Criteria: * American Society of Anesthesiologists (ASA) physical status I-III scheduled to undergo elective upper shoulder arthroscopic rotator cuff repair procedure Exclusion Criteria: * Patient refusal * pregnancy * skin infection at the site of block placement * history of allergy to local anaesthetic drugs * bleeding tendency or with evidence of coagulopathy * pre-existing neurological deficit or neuromuscular disease.
Contact & Investigator
Manoj K Karmakar, MD
PRINCIPAL INVESTIGATOR
Chinese University of Hong Kong
Frequently Asked Questions
Who can join the NCT04941664 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 75 Years, studying Musculoskeletal Diseases or Conditions. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT04941664 currently recruiting?
Yes, NCT04941664 is actively recruiting participants. Contact the research team at aylawong@cuhk.edu.hk for enrollment information.
Where is the NCT04941664 trial being conducted?
This trial is being conducted at Shatin, Hong Kong.
Who is sponsoring the NCT04941664 clinical trial?
NCT04941664 is sponsored by Chinese University of Hong Kong. The principal investigator is Manoj K Karmakar, MD at Chinese University of Hong Kong. The trial plans to enroll 25 participants.